A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial)

被引：1
|
作者：
Mirza, M. R. [1 ,2 ]
Monk, B. J. [3 ]
Oza, A. [4 ]
Mahner, S. [5 ,6 ]
Redondo, A. [7 ,8 ]
Fabbro, M. [9 ,10 ]
Ledermann, J. [11 ,12 ]
Lorusso, D. [13 ,14 ]
Vergote, I. B. [15 ,16 ]
Rosengarten, O. [17 ,18 ]
Berek, J. [19 ]
Herrstedt, J. [20 ,21 ]
Tinker, A. V. [22 ]
Dubois, A. [23 ,24 ]
Gonzalez Martin, A. [25 ,26 ]
Follana, P. [27 ,28 ]
Benigno, B. [29 ]
Rimel, B. J. [30 ]
Agarwal, S. [31 ]
Matulonis, U. [32 ]
机构：
[1] NSGO, Dept Oncol 5073, Copenhagen, Denmark
[2] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark
[3] Univ Arizona, Canc Ctr Phoenix, Dept Oncol, Phoenix, AZ USA
[4] Univ Hlth Network, Dept Oncol, Toronto, ON, Canada
[5] AGO, Dept Gynegol, Hamburg, Germany
[6] Univ Munich, Hamburg, Germany
[7] GEICO, Dept Oncol, Madrid, Spain
[8] Univ Hosp, Madrid, Spain
[9] GINECO, Dept Oncol, Montpellier, France
[10] Inst Canc Montpellier, Montpellier, France
[11] NCRI, Dept Med Oncol, London, England
[12] UCL, London, England
[13] MITO MaNGO, Dept Gynecol Oncol, Milan, Italy
[14] Fdn IRCCS Natl Canc Inst, Milan, Italy
[15] BGOG, Dept Obstet & Gynecol, Leuven, Belgium
[16] Univ Leuven, Leuven, Belgium
[17] ISGO, Dept Gynecol Oncol, Jerusalem, Israel
[18] Shaare Zedek Med Ctr, Jerusalem, Israel
[19] Stanford Womens Canc Ctr, Dept Oncol, Stanford, CA USA
[20] NSGO, Dept Oncol, Odense, Denmark
[21] Odense Univ Hosp, Odense, Denmark
[22] British Columbia Canc Agcy, Dept Med, Vancouver, BC, Canada
[23] AGO, Dept Oncol, Essen, Germany
[24] Kliniken Essen Mitte, Essen, Germany
[25] GEICO, Med Oncol Dept, Madrid, Spain
[26] MD Anderson Canc Ctr Madrid, Madrid, Spain
[27] GINECO, Dept Med Oncol, Nice, France
[28] Ctr Antoine Lacassagne, Nice, France
[29] Univ Gynecol Oncol, Dept Gynecol Oncol, Atlanta, GA USA
[30] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, West Hollywood, CA USA
[31] Tesaro Inc, Dept Med Affairs, Waltham, MA USA
[32] Dana Farber Canc Inst, Dept Gynecol Oncol, Boston, MA 02115 USA
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw435.26
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA3_PR
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Individualized starting dose of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC): A randomized, double-blind, placebo-controlled, phase III trial (NORA)
    Wu, X.
    Zhu, J.
    Yin, R.
    Yang, J.
    Liu, J.
    Wang, J.
    Wu, L.
    Liu, Z.
    Gao, Y.
    Wang, D.
    Lou, G.
    Yang, H.
    Zhou, Q.
    Kong, B.
    Huang, Y.
    Chen, L.
    Li, G.
    An, R.
    Wang, K.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1160 - S1161
  • [22] Safety Assessment of Niraparib Individualized Starting Dose in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: The Randomized, Double-Blind, Placebo-Controlled, Phase III NORA Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 13 - 14
  • [23] Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial.
    Wang, Jing
    Wu, Xiaohua
    Zhu, Jianqing
    Yin, Rutie
    Yang, Jiaxin
    Huang, Qidan
    Wu, Lingying
    Liu, Ziling
    Gao, Yunong
    Wang, Danbo
    Lou, Ge
    Yang, Hongying
    Zhou, Qi
    Kong, Beihua
    Huang, Yi
    Chen, Lipai
    Li, Guiling
    An, Ruifang
    Tan, Tao
    Dong, Juan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
    Li, Ning
    Zhang, Youzhong
    Wang, Jing
    Zhu, Jianqing
    Wang, Li
    Wu, Xiaohua
    Yao, Desheng
    Wu, Qiang
    Liu, Jihong
    Tang, Junying
    Yin, Rutie
    Lou, Ge
    An, Ruifang
    Zhang, Guonan
    Xia, Xiaoping
    Li, Qingshui
    Zhu, Yaping
    Zheng, Hong
    Yang, Xinfeng
    Hu, Yuanjing
    Zhang, Xin
    Hao, Min
    Huang, Yi
    Lin, Zhongqiu
    Wang, Dong
    Guo, Xiaoqing
    Yao, Shuzhong
    Wan, Xiaoyun
    Zhou, Huaijun
    Yao, Liangqing
    Yang, Xielan
    Cui, Heng
    Meng, Yuanguang
    Zhang, Songling
    Qu, Jing
    Zhang, Ben
    Zou, Jianjun
    Wu, Lingying
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (22) : 2436 - +
  • [25] Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial
    Matulonis, Ursula A.
    Walder, Lydia
    Nottrup, Trine J.
    Bessette, Paul
    Mahner, Sven
    Gil-Martin, Marta
    Kalbacher, Elsa
    Ledermann, Jonathan A.
    Wenham, Robert M.
    Woie, Kathrine
    Lau, Susie
    Marme, Frederik
    Casado Herraez, Antonio
    Hardy-Bessard, Anne-Claire
    Banerjee, Susana
    Lindahl, Gabriel
    Benigno, Benedict
    Buscema, Joseph
    Travers, Karin
    Guy, Holly
    Mirza, Mansoor R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (34) : 3183 - 3191
  • [26] Safety and dose modification for patients with low body weight receiving niraparib in the ENGOT-OV16/NOVA phase III trial
    Lord, R.
    Mirza, M. R.
    Woelber, L.
    Lesoin, A.
    Pineda, M. J.
    Peen, U.
    Hazard, S. J.
    Matulonis, U. A.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 11 - 11
  • [27] Efficacy and safety of niraparib in Chinese patients with platinum-sensitive recurrent ovarian cancer (NORA) with individualized starting dose: A subgroup analysis of a randomized, double-blind, placebo-controlled, phase III trial
    Wu, X.
    Zhu, J.
    Yin, R.
    Yang, J.
    Liu, J.
    Wang, J.
    Wu, L.
    Liu, Z.
    Gao, Y.
    Wang, D.
    Lou, G.
    Yang, H.
    Zhou, Q.
    Kong, B.
    Huang, Y.
    Chen, L.
    Li, G.
    An, R.
    Wang, K.
    Zhang, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1335 - S1335
  • [28] Time without symptoms or toxicity in patients with recurrent ovarian cancer receiving niraparib maintenance treatment versus placebo: A TWIST analysis of the ENGOT24-OV16/NOVA trial
    Matulonis, U. A.
    Walder, L.
    Nottrup, T. J.
    Tinker, A. V.
    Mahner, S.
    Gil-Martin, M.
    Fabbro, M.
    Banerjee, S.
    Wenham, R. M.
    Woie, K.
    Gilbert, L.
    Harter, P.
    Casado Herraez, A.
    Follana, P.
    Ledermann, J. A.
    Leroy, C.
    Scollo, P.
    Lund, B.
    Malander, S.
    Fisher, M.
    Guy, H.
    Mirza, M. R.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 2 - 2
  • [29] Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
    Pujade-Lauraine, Eric
    Ledermann, Jonathan A.
    Selle, Frederic
    Gebski, Val
    Penson, Richard T.
    Oza, Amit M.
    Korach, Jacob
    Huzarski, Tomasz
    Poveda, Andres
    Pignata, Sandro
    Friedlander, Michael
    Colombo, Nicoletta
    Harter, Philipp
    Fujiwara, Keiichi
    Ray-Coquard, Isabelle
    Banerjee, Susana
    Liu, Joyce
    Lowe, Elizabeth S.
    Bloomfield, Ralph
    Pautier, Patricia
    LANCET ONCOLOGY, 2017, 18 (09): : 1274 - 1284
  • [30] Food effect substudy of a phase 3 randomized double-blind trial of maintenance with niraparib (MK4827), a poly(ADP)ribose polymerase (PARP) inhibitor versus placebo in patients with platinum-sensitive ovarian cancer
    Moore, Kathleen N.
    Zhang, Zhi-Yi
    Agarwal, Shefall
    Patel, Manish R.
    Burris, Howard A.
    Martell, Robert E.
    Kansra, Vikram
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345